Catalyst Dossier · compiled by CeliA 🧫
BeiGene, Ltd. (BGNE)
Biotechnology · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-18 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-10-18 (est.)Phase 2 · BGB-45035imp 7/10
- 2026-10-28 (est.)Phase 2 · Zanubrutinibimp 7/10
- 2026-11-15 (est.)Phase 2 · Tislelizumab (BGB-A317)imp 7/10
- 2026-12-31 (est.)Phase 2 · Zanubrutinib Oral Productimp 7/10
- 2027-03-15 (est.)Phase 2 · Zanubrutinib Pillimp 7/10
- 2027-06-15 (est.)Phase 2 · Zanubrutinibimp 7/10
- 2027-06-30 (est.)Phase 3 · Fluorouracil (5-FU)imp 9/10
- 2027-06-30 (est.)Phase 3 · BGB-A425imp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| LBL-007 | Phase 2 | Non-small Cell Lung Cancer |
| Gemcitabine Hydrochloride | Phase 3 | Urothelial Carcinoma |
| Tislelizumab | Phase 3 | Urothelial Carcinoma |
| SX-682 | Phase 2 | Pancreatic Cancer |
| Tislelizumab (BGB-A317) | Phase 2 | MSI-H/dMMR Solid Tumors |
| Cisplatin injection | Phase 3 | Non Small Cell Lung Cancer |
| Zanubrutinib | Phase 3 | Refractory Mantle Cell Lymphoma |
| BGB-10188 | Phase 2 | Chronic Lymphocytic Leukemia |
| BGB-A445 | Phase 2 | Non-Small Cell Lung Cancer |
| BGB-A425 | Phase 2 | Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2 |
| lenvatinib | Phase 2 | Advanced Solid Tumor |
| Supportive Care | Phase 2 | COVID-19 Pulmonary Complications |
| BGB-16673 | Phase 3 | Chronic Lymphocytic Leukemia |
| BGB-11417 | Phase 2 | Mantle Cell Lymphoma |
| 5-fluorouracil | Phase 3 | Resectable Esophageal Squamous Cell Carcinoma |
| Pamiparib capsule | Phase 3 | Ovarian Cancer |
| Chemotherapy Doublet | Phase 2 | Esophageal Cancer |
| Fruquintinib | Phase 2 | Advanced Solid Tumors |
| Sonrotoclax | Phase 3 | Chronic Lymphocytic Leukemia |
| Pamiparib | Phase 2 | Brain and Central Nervous System Tumors |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BGNE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.